{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-2-study-of-brentuximab-vedotin-plus-cyclophosphamide-doxorubicin-etoposide-and-prednisone-chep-bv-followed-by-bv-consolidation-in-patients-with-cd30-positive-peripheral-t-cell-lymphomas\/#breadcrumbitem"}]}